A 40 amino acid region of Oct-2 from amino acids 142 to 181 functions as an active repressor domain capable of inhibiting both basal activity and activation of promoters containing a TATA box, but not of those that contain an initiator element. Based on our observation that the equivalent region of the closely related Oct-1 factor does not act as an inhibitory domain, we have mutated specific residues in the Oct-2 domain in an attempt to probe their importance in repressor domain function. Although mutations of several residues have no or minimal effect, mutation of proline 175 to arginine abolishes the ability to inhibit both basal and activated transcription. In contrast, mutation of proline 174 to arginine confers upon the domain the ability to repress activation of an initiator-containing promoter by acidic activation domains, and also suppresses the effect of the proline 175 mutation. Hence, adjacent proline residues play key roles in the functioning of the inhibitory domain and in limiting its specificity to TATA-box-containing promoters.
INTRODUCTION
The Oct-2 transcription factor is a founder member of the POU (Pit-Oct-Unc) family of transcription factors (for review see 1, 2) . This factor was originally considered to be expressed only in B lymphocytes, where it is involved in activating the expression of specific genes expressed in these cells (3) (4) (5) . In agreement with this idea, mice in which the gene encoding Oct-2 has been inactivated show defects in B-cell maturation (6) and fail to express specific genes, such as those encoding CD36 (7) and .
Although Oct-2 is absent in most non B-cell types (3, 4) , it has been detected by a number of groups, including our own, in neuronal cells (9) (10) (11) (12) (13) . However, in neuronal cells, Oct-2 appears to act predominantly as a repressor of gene expression rather than as an activator, as occurs in B cells. Thus, initial studies showing that Oct-2 could inhibit the activity of artificial promoters containing its octamer binding site (13, 14) and of the herpes simplex virus immediate early promoters, which contain the octamer-related TAATGARAT motif (11, 15) , have now been supplemented by the finding that it can also repress the promoters of the cellular tyrosine hydroxylase (16) and synapsin I (17) genes.
This difference between the activity of Oct-2 in B cells and neuronal cells arises because the primary transcript derived from the single gene encoding Oct-2 is alternatively spliced to produce mRNAs encoding different isoforms (18) . This alternative splicing takes place in a tissue-specific manner so that different isoforms predominate in neuronal cells and B cells (19) . Thus, Oct-2.1, which is the predominant form in B lymphocytes, contains a C-terminal activation domain that is absent in Oct-2.4 and 2.5, the forms that predominate in neuronal cells (18, 19) . Moreover, several groups including our own have shown that the N-terminal region of Oct-2 has an inhibitory effect on transcription (20) (21) (22) . In particular, we have identified a 40 amino acid region near the N-terminus of the protein (amino acids 142-181) that is common to Oct-2.1, Oct-2.4 and Oct-2.5 and is essential for the observed inhibitory effect on transcription (20) . A similar N-terminal domain common to Oct-2.1, 2.4 and 2.5 has also been identified between amino acids 42 and 64 of Oct-2.1 (21) . Thus, in Oct-2.1 the strong C-terminal activation region overcomes the effect of the inhibitory N-terminal domain resulting in transcriptional activation in B cells (19, 20) . In contrast, in the absence of this C-terminal activation domain, as in Oct-2.4 and Oct-2.5, the N-terminal inhibitory region is able to act to repress transcription (19, 20) . An inhibitory region unique to the Oct-2.3 isoform has also been identified and consists of an additional 22 amino acids located near the N-terminus of the molecule between positions 72-73 of Oct-2.1 (22) .
Thus, the N-terminal region of Oct-2 contains several regions capable of inhibiting transcription. These domains were all identified on the basis of their inhibitory effect on transcriptional activation mediated via the activation domains of Oct-2 itself. However, we have shown recently that only the inhibitory domain located between amino acids 142 and 181, which we identified, can function as a transferable inhibitory domain that can inhibit the basal activity of a promoter or its activation by heterologous *To whom correspondence should be addressed. Tel: +44 171 380 9343; Fax: +44 171 387 3310; Email: d.latchman@ucl.ac.uk activation domains, whereas the other two inhibitory domains are inactive in these assays (23) .
Thus, when linked to the DNA binding domain of a heterologous transcription factor such as Gal4, the 142-181 inhibitory domain can repress a variety of promoters containing GAL4 binding sites in mammalian cells (20, 24, 25) . Since no positive-acting factors binding to such sites exist in mammalian cells, this eliminates models in which the Oct-2 factor simply acts as a passive repressor, blocking the access of activating molecules to its binding site. Similarly, since this inhibitory domain cannot repress transcription when it is not linked to a DNA binding domain (20, 24) , it does not appear to function by removing activators from the DNA by formation of a non-DNA binding complex.
In subsequent studies with the 142-181, Oct-2 inhibitory domain we demonstrated that it was also able to inhibit gene activation by a wide variety of activation domains when these are delivered to distinct sites within the promoter (25) . The ability of the inhibitory domain to achieve this effect with a wide variety of different activation domains (including acidic, glutamine-rich or proline-rich domains) argues against its directly interacting with activation domains to quench their activity, since such quenching repressers usually only inhibit a single type of activation domain (26) (27) . This suggests that this Oct-2 inhibitory domain inhibits transcription in an active manner by interacting with the downstream target of transcriptional activators, within the basal transcriptional complex. In agreement with this idea, this Oct-2 inhibitory domain is able to inhibit the function of transcriptional activators only when the promoter contains a TATA box, and not when this motif is substituted with an initiator motif (25) . In view of the unique ability of this 142-181 domain to act as a direct inhibitor of transcription, we have analyzed its activity further.
MATERIALS AND METHODS

Site-directed mutagenesis
Polymerase chain reaction (PCR) mutagenesis was used to produce copies of the inhibitory domain with mutations at bases encoding amino acids Q-167, E-173, P-174 and P-175.
The PCR primers used were as follows. External primers: Primer 1, 5′-GATCGAATTCGGCTACCAACGCCAAATCTA-3′; Primer 5, 5′-GATCGAATTCGGTGATGCGGCGTTGCTGA-3′. Internal mutagenic primers: Primer 2, 5′-CCCCCCAAATGCTT-GG/A/CAGCNACCA-3′; Primer 3, 5′-CCCCCCAAATGCTT-GGAGCCACNA-3′; Primer 4, 5′-CAAGCATTTGGGGGGCT-C/G/TTGT-3′. PCR amplification was initially carried out with primers 1 and 4, primers 2 and 5 or primers 3 and 5, with subsequent amplification of the PCR products being carried out with primers 1 and 5.
Subsequently, the mutated PCR products were digested with the restriction enzyme EcoRI and cloned either into the pSG4 vector linking the inhibitory domain to the DNA binding domain of GAL4 (28) or into the pTETR vector (24) linking it to the DNA binding domain of the tetracycline repressor.
Subsequent PCR amplifications designed to mutate P-174 and P-175, either singly or in combination, were carried out with the primers 5′-CCCCCGAAATGCTTGGAGCG/CGCG/CC-3′ and 5′-CAAGCATTTGGGGGGTTTACGAAC-3′, and the resulting PCR products were cloned as described above.
Plasmid DNAs
The effect of the mutant inhibitory domains on basal promoter activity was tested using the Gal-TK-CAT reporter, which contains five Gal4 binding sites cloned at position -105 relative to the transcriptional start site of the HSV thymidine kinase gene promoter (29) . Similarly, the effect of transcriptional activators was tested using the T7G5-TATA or T7G5-INR constructs, which contain seven binding sites for the tetracycline repressor DNA binding domain and five binding sites for Gal4 cloned upstream of either a TATA box or an initiator motif, respectively (24, 30) . These constructs were used in conjunction with a number of different plasmids containing different activation domains linked to the DNA binding domain of GAL4 which have been described previously (24) .
Transfections
BHK-21 cells clone 13 (31) and ND7 cells (32) were transfected by the method of Gorman (33) . Assays of CAT activity in the transfected cells were carried out as described by Gorman (33) , extracts having been previously equalized for protein content by the method of Bradford (34) . The percentage conversion of chloramphenicol to the acetylated form was determined by analysis on a PhosphorImager (Bio-Rad). In all cases, the values obtained were equalized for differences in plasmid uptake between the different samples based on the results of dot blot hybridization of an aliquot of the transfected cell extract with a DNA probe derived from the ampicillin resistance gene in the plasmid vector (35) .
RESULTS
As a first step to identifying the critical features of the 142-181, Oct-2 inhibitory domain, we wished to determine whether the equivalent region of the closely related transcription factor Oct-1 would also be able to inhibit transcription. We therefore prepared a construct in which the equivalent region of Oct-1 was linked to the DNA binding domain of Gal4 and determined its effect on the Gal-TK-CAT reporter construct, which contains five DNA binding sites for Gal4 (see Fig. 1 for details of all the constructs used in this report). As illustrated in Figure 2 , the Oct-1 construct was unable to repress the activity of the reporter when co-transfected into BHK fibroblast cells, although the equivalent region of Oct-2 was able to do so, in accordance with our previous results.
As this region of Oct-1 is ∼50% homologous to the equivalent region of Oct-2 ( Fig. 3) , this suggested that some of these amino acid differences between Oct-1 and Oct-2 would be critical for the functioning of the inhibitory domain. We therefore carried out site-directed mutagenesis with the aim of altering specific amino acids that were different between Oct-1 and Oct-2. To maximise the chance of achieving an effect, PCR mutagenesis was used to simultaneously target either three residues (Q-167, E-173 and P-174) or two residues (Q-167 and P-175). The mutant inhibitory domains obtained in this way contained four different triple amino acid substitutions, two different double amino acid substitutions and one single amino acid substitution as determined by DNA sequence analysis. The various mutations obtained are indicated in Figure 3 and were designated 'M' followed by the letter representing the mutant amino acid obtained in the single letter code. In initial experiments we determined whether any of these mutations affected the ability of the mutant inhibitory domain to repress the TK promoter containing cloned Gal4 sites in BHK fibroblast cells. In these experiments (Fig. 4) , the wild-type domain was able to inhibit promoter activity in accordance with our previous results (20) , whilst the majority of the mutants did not reduce the activity of the inhibitory domain, and indeed some of the mutations appeared to enhance its activity. However, the activity of the inhibitory domain was essentially abolished in the mutant MKR, which not only failed to repress the promoter but actually stimulated it to a small extent, as is observed for Oct-1. Thus, the combination of mutating glutamine 167 to lysine and proline 175 to arginine completely abolishes the ability of the inhibitory domain to repress the activity of this promoter. Interestingly, this effect is sequence-specific, since mutations at these two positions to glutamic acid and leucine (mutant MEL) retain the inhibitory effect. All the mutants were expressed at similar levels, as determined by western blotting of transfected cell extracts. In particular, the MKR mutant was expressed at a similar level to the wild-type Oct-2 inhibitory domain ( Fig. 5 ), indicating that its lack of inhibitory effect was not due to a failure of this mutant to produce sufficient protein. A similar failure of the MKR mutant to repress the target promoter was observed in the ND7 neuronal cell line (data not shown), indicating that this effect is not specific to BHK cells.
Having identified a combination of mutations which could affect the ability of the inhibitory domain to repress the basal activity of a promoter, we wished to determine its effect on the activation of promoters by different classes of activation domain. To do this, we used the system we have used previously (25) , in which the target promoter contains seven binding sites for the tetracycline repressor DNA binding domain upstream of five binding sites for the Gal4 factor (Fig. 1) . The effect of the Oct-2 inhibitory domain on activator domains can therefore be tested in transfection experiments with this reporter and constructs containing the Oct-2 inhibitory domain linked to the tetracycline repressor DNA binding domain, and various activation domains linked to the DNA binding domain of Gal4 (Fig. 1) .
The reporter constructs used in these assays contain the very weak E1B promoter and are therefore unsuitable for testing for repression of basal activity in the absence of any activator, since they give a barely detectable basal activity. However, in initial experiments, we tested the effect of each of the mutants on the basal activity of these reporters, using a set of identical reporters which differ only in the possession of a TATA box, an initiator element or both elements combined (25, 30) . As expected, in these experiments (Fig. 6 ) it was not possible to reliably assess the inhibitory effect of the wild-type Oct-2 domain due to the weak activity of the promoter. However, on all three promoters, the MKR mutant showed a clear stimulatory effect on the promoter which was most dramatic in the case of the promoters containing a TATA box either alone or together with an initiator element.
This suggests, that despite the weak basal activity of this promoter, the Oct-2 inhibitory domain does exert an inhibitory effect on the promoter. When this is eliminated, as in the MKR mutant, a stimulatory effect is observed. This may reflect the fortuitous creation of an activation domain via the substitutions which we have introduced or, more likely, a weak stimulatory effect of the N-terminal portion of the inhibitory domain. Thus, this region overlaps the boundaries of an N-terminal activation domain previously mapped within the Oct-2 factor (36,37). Whatever the precise explanation for this effect, it indicates the dramatic effect of the MKR mutation on another promoter distinct from that investigated previously. Moreover, this finding provides further evidence that the lack of inhibitory effect of this protein is not due to phenomena such as rapid degradation or sequestration in a non-nuclear compartment which would evidently also prevent it activating transcription.
We next investigated the effects of the mutations on the ability of different activators to stimulate these promoters. In all cases, results were compared with the activity of the same promoter in the absence of any activator so as to control for the stimulatory effect of the MKR mutant on these promoters. In these experiments, the activity of the wild-type and mutant inhibitory domains was tested against several different classes of activation domains, derived from VP16 (acidic) Sp1 (glutamine-rich) CTF (proline-rich) and the HOB motif from the cFos activation domain (Fig. 1) . In these experiments (Fig. 7a-d) , whilst the wild-type Oct-2 domain was able to strongly inhibit activation by all four domains in accordance with our previous results (25) , the MEL, MEKR and MERQ mutants did show some reduction in inhibitory activity on one or more of the activation domains tested. In no case however, did this result in total abolition of the activity. Similarly, the MERL mutant had virtually no effect on the activity of the inhibitory domain and in some cases appeared to repress transcription better than the wild-type domain. 
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In contrast, the MKR mutant resulted in a total abolition of the ability of the inhibitory domain to interfere with acidic, proline-rich and HOB activation domains and a virtually complete abolition of its ability to repress a glutamine-rich domain. Thus, these findings indicate that the combination of substituting the glutamine residue at position 167 with a lysine, and the substitution of the proline residue at position 175 with an arginine abolishes the activity of the inhibitory domain. In contrast, similar substitution of position 167 with a glutamic acid and position 175 with a lysine residue does not appear to have any dramatic effect on the inhibitory domain. Similarly, in these assays we were unable to detect any significant effect of substituting the glutamic acid at position 173 and the proline residue at 174 with several other amino acids even when this was also combined with substitutions at position 167.
In our previous experiments (25), we showed that the inhibitory domain was unable to repress the action of specific activation domains when the promoter contained an initiator motif rather than a TATA box. In order to investigate the effect of our mutant inhibitory domains on this aspect, we repeated our experiments using the same delivery system to deliver the Oct-2 inhibitory domain and the activation domains but using a target promoter in which the TATA box had been substituted with an initiator motif (Fig. 1) . In these experiments (Fig. 8a-d) , the wild-type inhibitory domain was, as expected, unable to interfere with the ability of several different activation domains to activate the initiatorcontaining promoter. This absence of any inhibitory effect occurred with the activation domains of VP16 (acidic) Sp1 (glutamine-rich) the proline rich activation domain of CTF and the HOB activation domain of cFos ( Fig. 8a-d) . Similarly, several different mutants were unable to repress these different activation domains and this included the MKR mutant, which as shown above is inactive on TATA-box containing promoters also.
Most surprisingly however, the MEKR mutant was able to repress activation by the acidic domain of VP16 although it could not repress activation by the other domains (Fig. 8a-d) . These results therefore indicate that it is possible to create a mutant Oct-2 inhibitory domain which can repress the activity of an acidic activation domain on an initiator-containing promoter. This effect is achieved, in our mutant, by the substitution of the glutamine residue at position 167 with glutamic acid, together with the substitution of the glutamic acid at position 173 with lysine and the proline at position 174 with arginine.
The experiments described above have therefore allowed us to identify combinations of mutations in the Oct-2 inhibitory domain that can either abolish its activity or allow it to interfere with the activity of some activation domains when located upstream of an initiator-containing promoter. As both the mutant inhibitory domains that we showed to produce these effects contained more than one amino acid mutation, we wish to determine whether these effects were in fact dependent on one of the mutations which have been produced. In the case of the MEKR mutant, which was able to repress an initiator-containing promoter, two of the mutations it contains were also present in either the MRKL mutant or the MERL mutant, neither of which had any effect on the lack of ability of the inhibitory domain to repress an initiator containing promoter. We therefore postulated that the mutation in proline 174 was the key feature of this mutant. Similarly, mutation at position 167 did not appear to produce any effects in any of the mutants, suggesting that it was the change in proline 175 that was responsible for inactivating the inhibitory domain in the MKR mutant. We therefore produced a second series of mutations in which proline 174 or proline 175 were changed to arginine either alone or in combination, and tested the effect of these mutations in our assays. When these mutants were tested for their ability to repress the basal activity of the Gal-TK-CAT, mutation of proline 175 in the PR mutant virtually abolished the ability of the inhibitory domain to repress the basal activity of the promoter (Fig. 9 ). This confirms that the effect noted previously with the MKR mutant can be produced with mutation only of the proline residue to arginine. Interestingly, mutation of proline 174, as expected, did not reduce the ability of the inhibitory domain to repress this promoter and indeed appears to increase it. This increased inhibition was also noted in the RR mutant where both prolines had been changed to arginine, indicating that mutation of proline 174 can apparently compensate for the inactivating effect of mutating proline 175 in the PR mutant. As with the multiple mutants, all the single mutants were expressed at similar levels in the transfected cells, indicating that these effects are not due to differences in expression levels (data not shown).
The loss of inhibitory effect in the PR mutant was also observed when the mutant domain was tested for its ability to prevent the activation domain of VP16 from stimulating the T7 G5-TATA box containing promoter. As illustrated in Figure 10a , the PR mutation completely abolished the ability of the inhibitory domain to prevent VP16 activation and indeed produced some enhancement of the activation observed in the absence of the Figure 9 . CAT assay of the results of co-transfecting 10 µg of the GAL-TK-CAT plasmid with 10 µg of the expression vector encoding only the isolated Gal4 DNA binding domain or the same vector containing the wild-type inhibitory domain or the same domain in which either proline 174 has been changed to arginine (RP), or proline 175 has been changed to arginine (PR) or both prolines have been changed (RR). In all cases, the degree of CAT activity was compared with that observed in the presence of the expression vector containing only the isolated Gal4 DNA binding domain (set at 100%). Values are the average of four determinations whose standard deviation is shown by the bars. inhibitory domain. In contrast, some weak inhibition was observed with both the RP and the RR mutant. A similar loss of inhibitory activity of the PR mutant was observed when the activation domains of Sp1, CTF or c-Fos were used, confirming that this mutant showed the same widespread loss of inhibitory activity as the MKR mutant (data not shown). These results therefore confirm the importance of proline 175 in producing inhibitory effects on TATA box-containing promoters.
However, a different effect was observed when we tested the ability of the mutant inhibitory domains to interfere with activation by VP16 on the same promoter containing an initiator motif (Fig. 10b) . As expected, the wild-type repressor domain had no effect in this assay. However, the RP mutant, in which proline 174 has been changed to arginine, produced a significant inhibitory effect. This was also observed with the RR double mutant, whilst some weak inhibition was also observed with the PR mutant in this assay. Although this inhibitory effect of the PR mutant was unexpected since it was not observed in previous experiments with the MKR mutant, these results do make it clear that the proline residue at position 174 plays a critical role in the lack of ability of a wild-type initiator domain to repress an initiator-containing promoter.
A similar inhibitory effect of the RR and RP mutants on transactivation of the initiator-containing promoter by full length Gal4 containing an acidic activation domain was also observed, although the wild-type domain and the PR mutant had no effect as expected (data not shown). Hence, this effect is not unique to the acidic activation domain of VP16. Thus, the ability of the MEKR mutant to repress activation of initiator-containing promoters by acidic activation domains can be reproduced by a mutant containing only a proline to arginine mutation at position 174. However, this effect is confined to acidic activation domains since, as with the MEKR mutant, the RP mutant was unable to 
DISCUSSION
Our previous studies have characterized a 40 amino acid inhibitory domain in the Oct-2 transcription factor located between amino acids 142 and 181, which appears to act as an active repressor domain rather than as an indirect repressor, which acts by interfering with the activity of positive-acting transcription factors (for reviews of transcriptional repression, see [38] [39] [40] . Thus, the inhibitory domain does not act by competing with activators for their DNA binding site or by removing them from DNA by means of a protein-protein interaction (20, 24) . Similarly, the ability of the inhibitory domain to interfere with activation by a number of different activation domains (25) suggests that it interacts with their downstream target, namely the basal transcriptional complex, a finding also supported by the inability of the inhibitory domain to achieve this effect when an initiator motif is substituted for a TATA box in the target promoter.
A number of different direct-acting repressors have been described including several Drosophila factors such as engrailed, even-skipped and kruppel (41) , and the mammalian factors YY1 (42) WT1 (29) and E4BP4 (43) . In several cases, as with Oct-2, the specific transcriptional repressor domains have been identified (29, (41) (42) (43) (44) (45) . As with activation domains, different repressor domains appear to have different features. Thus, the identified repressor domains have been shown to be alanine-rich (44), highly basic (47, 48) , rich in charged residues (43) or rich in proline residues (29, 41, 48) . Moreover, in several cases these features have been shown to be of functional importance. Thus, for example, the mutation of a single glutamine to lysine in the repressor domain of the Drosophila Kruppel protein abolished its ability to repress transcription (44) and the basic amino acids in E4BP4 have similarly been shown to be of critical importance (43) .
In our study, we initially noted that the Oct-2 inhibitory domain contained a number of glutamine residues and a number of proline residues, several of which were not conserved in the equivalent region of Oct-1, which we showed to have no transcriptional inhibitory effect. Interestingly, we did not demonstrate any effect of mutating one of these glutamine residues or of a glutamic acid residue. However, we did demonstrate specific effects of mutating the proline residues at positions 174 and 175, either in combination with other mutations or subsequently in isolation.
It thus appears that the proline residues at these two adjacent positions are critical for the functioning of the Oct-2 inhibitory domain. In particular, if the proline residue at position 175 is mutated to arginine, the ability of Oct-2 to repress the basal activity of TATA box-containing promoters or their activation by specific activation domains is lost. Hence, this residue plays a critical role in the functioning of the inhibitory domain. Indeed, in some situations, the mutation of this residue converts Oct-2 from a repressor to an activator of specific promoters. This effect is probably dependent on a portion of the N-terminal activation domain defined previously by others (36, 37) being present within our inhibitory domain. Hence, when the inhibitory function of this domain is inactivated, this region can activate transcription.
Regardless of the mechanism responsible for transcriptional activation in some cases when proline 175 is inactivated, it is clear that this amino acid is essential for transcriptional repression to occur. In contrast, mutation of the adjacent proline 174 to arginine does not result in a failure of transcriptional repression. Rather, it confers upon Oct-2 the ability to repress activation of an initiator-containing promoter by acidic activation domains, which is not observed with the wild-type domain. Similarly, we also noted that whilst mutation at proline 175 abolishes repression of basal promoter activity, this effect is restored in a double mutant in which both proline 174 and 175 have been mutated. Hence, mutation at proline 174 can also substitute for mutation at proline 175 to allow continued repression of TATA box-containing promoters.
This suggests that proline 174 and proline 175 form a critical region that plays a key role in determining the function and specificity of the Oct-2 inhibitory domain. This would occur, for example, if this region of the domain interacts directly with a component of the basal transcriptional complex. Thus, mutation of proline 175 to arginine would, in this model, result in a failure of this interaction or prevent it from repressing transcription. The inability of Oct-2 to repress the basal transcriptional complex bound at an initiator could result from its target within the complex being specific to the complex assembled on TATA-boxcontaining promoters. Thus, for example, the TBP associated factors differ in the TFIID complexes formed at the initiator and at the TATA box (49) . Alternatively, Oct-2 could interact with a component common to both types of complex such as TBP (50) if such a component were in a different configuration when bound at the initiator and at the TATA box.
In this model, mutation at proline 174 would confer upon Oct-2 the ability to interact with the common component in the configuration it assumes at an initiator as well as that when it is bound at a TATA box. Alternatively, it might allow a novel interaction of Oct-2 with a component found only at initiator complexes, thereby widening the inhibitory abilities of Oct-2. In this regard, it is of particular interest that mutation at proline 174 also appears to be able to overcome the inactivating effect of mutation at proline 175, resulting in the double mutant still being able to repress the basal activity of a TATA-box-containing promoter, whereas the single proline 175 mutation cannot do so (Fig. 9) . It is probable, therefore, that these two adjacent amino acids act as a single interface determining the interaction of Oct-2 with specific component(s) of the basal transcriptional complex.
Although a full understanding of the interaction of the inhibitory domain of Oct-2 with the basal transcriptional complex must await protein-protein interaction and structural studies, the availability of single amino acid mutants which inhibit the activity of the Oct-2 inhibitory domain or change its specificity will greatly facilitate such an analysis. However, it is already clear that the adjacent proline residues at positions 174 and 175 play distinct but complementary roles in the functional activity of the complex being important, respectively, for the functioning of the inhibitory domain and its specificity for TATA-box-containing promoters.
